Kunyu Yang
A5089211608- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Ear and Head Tumors
- Immunotherapy and Immune Responses
- Salivary Gland Tumors Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Peptidase Inhibition and Analysis
- Nanoplatforms for cancer theranostics
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Immune cells in cancer
- Radiation Therapy and Dosimetry
- Lung Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cancer Cells and Metastasis
- Medical Imaging Techniques and Applications
- Lymphoma Diagnosis and Treatment
- Influenza Virus Research Studies
- Extracellular vesicles in disease
- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer-related molecular mechanisms research
Huazhong University of Science and Technology
2016-2025
Union Hospital
2016-2025
Wuhan Union Hospital
2006-2025
Hunan University of Technology
2024-2025
Second Hospital of Shandong University
2024
Shenzhen International Travel Health Care Center
2011-2024
Union Hospital
2022-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
Shanghai Entry-Exit Inspection and Quarantine Bureau
2017-2024
Sun Yat-sen University
2012-2024
Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials.
<h3>Importance</h3> This study demonstrates that tislelizumab in combination with chemotherapy is associated improved progression-free survival (PFS) patients advanced squamous non–small-cell lung cancer (sq-NSCLC). <h3>Objective</h3> To assess the efficacy and safety/tolerability of plus vs alone as first-line treatment for sq-NSCLC. <h3>Design, Setting, Participants</h3> open-label, randomized phase 3 clinical trial was conducted at 46 sites China between July 2018 June 2019 included...
Abstract Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has high incidence Southeast Asia North Africa. To develop these comprehensive guidelines for diagnosis management of NPC, Chinese Society Clinical Oncology (CSCO) arranged multi‐disciplinary team comprising experts from all sub‐specialties NPC to write, discuss, revise guidelines. Based on findings evidence‐based medicine China abroad, domestic have iteratively developed provide proper...
By mimicking the RIBE machinery, we provided an indirect radiotherapy approach based on RT-MP for eradication of MPE in mice.
Background: Tumor associated macrophages (TAMs) have strong plasticity and if reprogrammed, can clear tumor cells regulate the adaptive immune system for cancer immunotherapy. Deubiquitinating enzymes (DUBs), which remove ubiquitin (Ub) from Ub-modified substrates, been with oncogenic metabolism but are not well-known regulating TAMs repolarization. Methods: The expression of DUB related genes in (MΦs) was detected by reverse transcription-PCR. Flow cytometry immunofluorescence were used to...
Immunosuppressive tumor microenvironments (TMEs) create tremendous obstacles for an effective cancer therapy. Herein, we developed a melittin-RADA32 hybrid peptide hydrogel loaded with doxorubicin (DOX) potent chemoimmunotherapy against melanoma through the active regulation of TMEs. The formed melittin-RADA32-DOX (MRD) has interweaving nanofiber structure and exhibits excellent biocompatibility, controlled drug release properties both in vitro vivo, enhanced killing effect to cells. A...
Photodynamic therapy (PDT) is a clinical cancer treatment modality based on the induction of therapeutic reactive oxygen species (ROS), which can trigger immunogenic cell death (ICD). With aim simultaneously improving both PDT-mediated intracellular ROS production and ICD levels, we designed serum albumin (SA)-coated boehmite ("B"; aluminum hydroxide oxide) organic-inorganic scaffold that could be loaded with chlorin e6 (Ce6), photosensitizer, honey bee venom melittin (MLT) peptide, denoted...
Background In locally advanced rectal cancer (LARC), preoperative short-course radiotherapy (SCRT) with delayed surgery has been shown to be as effective long-course chemoradiotherapy, only modest benefits. This study aimed evaluate the efficacy and safety of SCRT combined subsequent CAPOX (capecitabine oxaliplatin) anti-PD-1 antibody camrelizumab in patients LARC. Methods was a prospective, single-arm, phase II trial. Treatment-naïve histologically confirmed T3-4N0M0 or T1-4N+M0...
Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4-6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo-chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p < 0.0001). PFS benefit observed regardless...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We previously reported significantly improved failure-free survival using gemcitabine plus cisplatin induction...
Importance There are currently no therapies approved by the US Food and Drug Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is current standard of care first-line treatment recurrent or metastatic NPC (RM-NPC). Objective To determine whether toripalimab in combination with gemcitabine-cisplatin will significantly improve progression-free survival overall as RM-NPC, compared alone. Design, Setting, Participants JUPITER-02 an international, multicenter, randomized,...
Abstract Purpose: This study aimed to assess the antitumor activity and safety of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab in patients locally advanced head neck squamous cell carcinoma (HNSCC). Patients Methods: In this single-center, single-arm, phase 2 trial, resectable stage III–IVB HNSCC received [albumin-bound paclitaxel 260 mg/m2 (or docetaxel 75 mg/m2) plus cisplatin mg/m2] 200 mg on day 1 each 21-day cycle for three cycles, followed by surgery, adjuvant...
Abstract Malignant ascites in advanced hepatocellular carcinoma (HCC) is a complex clinical problem that lacks effective treatments. Due to the insensitivity of HCC cells traditional chemotherapies, low drug accumulation, and limited residence time peritoneal cavity, therapeutic effects malignant are not satisfactory. In this study, an injectable hydrogel delivery system based on chitosan hydrochloride oxidized dextran (CH‐OD) designed load sulfasalazine (SSZ), FDA‐approved with...
The AJCC/UICC TNM classification describes anatomic extent of tumor progression and guides treatment decisions. Our comprehensive analysis 8,834 newly diagnosed patients with non-metastatic Epstein-Barr virus related nasopharyngeal carcinoma (NPC) from six Chinese centers indicates certain limitations in the current staging system. 8th edition inadequately differentiates patient outcomes, particularly between T2 T3 categories within N classification. We propose reclassifying cases NPC early...
Background Immune checkpoint inhibitors (ICIs) in combination with antiangiogenic drugs have shown promising outcomes the third-line and subsequent treatments of patients microsatellite stable metastatic colorectal cancer (MSS-mCRC). Radiotherapy (RT) may enhance antitumor effect immunotherapy. However, RT exposure on receiving ICIs targeted therapy remains unclear. This study aimed to investigate association between clinical responses fruquintinib (a highly selective tyrosine kinase...